Total Payments
$1.2M
2024 Payments
$72,441
Companies
6
Transactions
384
Medicare Patients
295
Medicare Billing
$30,164
Payment Breakdown by Category
Consulting$1.1M (89.6%)
Travel$75,205 (6.4%)
Research$36,538 (3.1%)
Food & Beverage$11,248 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.1M | 81 | 89.6% |
| Travel and Lodging | $75,205 | 77 | 6.4% |
| Unspecified | $36,538 | 56 | 3.1% |
| Food and Beverage | $11,248 | 170 | 1.0% |
Payments by Type
General
$1.1M
328 transactions
Research
$36,538
56 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1.0M | 278 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $106,889 | 76 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $33,466 | 21 | $0 (2024) |
| Gilead Sciences Inc | $2,400 | 3 | $0 (2017) |
| Novo Nordisk AS | $1,575 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $268.99 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $72,441 | 25 | Alexion Pharmaceuticals, Inc. ($33,283) |
| 2023 | $85,837 | 63 | Bayer Healthcare Pharmaceuticals Inc. ($59,554) |
| 2022 | $255,811 | 85 | GlaxoSmithKline, LLC. ($224,559) |
| 2021 | $143,750 | 12 | GlaxoSmithKline, LLC. ($143,750) |
| 2020 | $121,231 | 14 | GlaxoSmithKline, LLC. ($121,231) |
| 2019 | $243,103 | 73 | GlaxoSmithKline, LLC. ($243,103) |
| 2018 | $136,388 | 44 | GlaxoSmithKline, LLC. ($136,388) |
| 2017 | $124,653 | 68 | GlaxoSmithKline, LLC. ($121,984) |
All Payment Transactions
384 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/18/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $98.41 | General |
| 09/13/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $115.08 | General |
| Category: Rare Disease | ||||||
| 07/30/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $110.04 | General |
| 07/30/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $106.40 | General |
| 06/24/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $26,130.00 | General |
| 05/11/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $145.97 | General |
| 05/03/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $58.43 | General |
| Category: Rare Disease | ||||||
| 05/03/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $11.41 | General |
| 05/02/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $85.77 | General |
| Category: Rare Disease | ||||||
| 05/02/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: Rare Disease | ||||||
| 05/01/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $33.48 | General |
| Category: Rare Disease | ||||||
| 04/30/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $57.70 | General |
| 04/30/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $49.95 | General |
| Category: Rare Disease | ||||||
| 04/30/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $33.53 | General |
| Category: Rare Disease | ||||||
| 04/30/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $8.41 | General |
| 04/29/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $1,346.53 | General |
| Category: Rare Disease | ||||||
| 04/29/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $82.20 | General |
| Category: Rare Disease | ||||||
| 04/29/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $63.37 | General |
| Category: Rare Disease | ||||||
| 04/28/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $4,721.70 | General |
| Category: Rare Disease | ||||||
| 04/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $147.55 | General |
| Category: Cardio-renal | ||||||
| 03/20/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $17,875.00 | General |
| 03/20/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 02/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $13,800.00 | General |
| Category: Cardio-renal | ||||||
| 01/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $2,012.50 | General |
| Category: Cardio-renal | ||||||
| 01/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $122.78 | General |
| Category: Cardio-renal | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 randomized, open label sponsor blind , active controlled, parallel group, multi center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to re | GlaxoSmithKline, LLC. | $16,110 | 14 |
| A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | GlaxoSmithKline, LLC. | $7,822 | 29 |
| A Phase 3 randomized, open label sponsor blind , active controlled, parallel group, multi center, event driven study in non dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared t | GlaxoSmithKline, LLC. | $214.18 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 53 | 85 | $26,236 | $5,033 |
| 2022 | 5 | 97 | 189 | $53,022 | $11,512 |
| 2021 | 4 | 67 | 107 | $30,504 | $6,557 |
| 2020 | 4 | 78 | 125 | $33,277 | $7,061 |
Total Patients
295
Total Services
506
Medicare Billing
$30,164
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 25 | 49 | $14,504 | $2,954 | 20.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 22 | $6,034 | $1,097 | 18.2% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 14 | 14 | $5,698 | $981.82 | 17.2% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 32 | 102 | $29,376 | $6,432 | 21.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $7,490 | $1,637 | 21.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 22 | $6,226 | $1,357 | 21.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 23 | 35 | $5,600 | $1,168 | 20.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 16 | $4,330 | $918.61 | 21.2% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 25 | 53 | $15,847 | $3,315 | 20.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 13 | 13 | $7,293 | $1,529 | 21.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 18 | 27 | $4,320 | $895.59 | 20.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 14 | $3,044 | $817.21 | 26.8% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2020 | 25 | 58 | $16,936 | $3,722 | 22.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 23 | 33 | $6,772 | $1,370 | 20.2% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 13 | 13 | $5,265 | $1,161 | 22.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 17 | 21 | $4,304 | $807.29 | 18.8% |
About Dr. Ajay Singh, MD
Dr. Ajay Singh, MD is a Nephrology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376551382.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ajay Singh, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $72,441 received in 2024. These payments were reported across 384 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($1.1M).
As a Medicare-enrolled provider, Singh has provided services to 295 Medicare beneficiaries, totaling 506 services with total Medicare billing of $30,164. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Boston, MA
- Active Since 08/04/2006
- Last Updated 04/20/2012
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1376551382
Products in Payments
- Kerendia (Drug) $106,787
- ULTOMIRIS (Biological) $6,615
- MAA868 (Drug) $80.99
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Boston
David Friedman, M.d, M.D
Nephrology — Payments: $20.3M
Nephrology $20.3M
Martin Pollak, Md, MD
Nephrology — Payments: $20.3M
Nephrology $20.3M
Dr. Dennis Ausiello, Md, MD
Nephrology — Payments: $4.4M
Nephrology $4.4M
Dr. Leslie Fang, Md, MD
Nephrology — Payments: $795,357
Nephrology $795,357
Dr. Jean Francis, M.d, M.D
Nephrology — Payments: $217,413
Nephrology $217,413
Joseph Bonventre, Md Phd, MD PHD
Nephrology — Payments: $178,338
Nephrology $178,338